LABA/LAMA vs LABA plus inhaled corticosteroid (ICS)
Change in baseline trough FEV1 · stable COPD
Long‐acting muscarinic antagonist (LAMA) plus long‐acting… probably leads to higher trough FEV1 change from baseline compared with LABA plus inhaled corticosteroid (ICS) (moderate certainty).
1 finding from 1 review
- Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid… 2023 · Cochrane Headline outcomes onlyMD 0.07 [0.05, 0.08]12 studies · 14681 participantsModerate